Kornimate/medical-research-clean huggingface dataset:
assess the efficacy and safety of shr0302 ointment in adult patients with vitiligo

Conditions: Vitiligo

Summary: the purpose of this study is to assess the efficacy and safety of shr0302 ointment in adult patients with vitiligo.

this study is a phase ii/ⅲ seamless adaptive clinical trial to evaluate the efficacy and safety of shr0302 ointment in adult patients with non-segmental vitiligo.

Eligibility criteria:
inclusion criteria: 1. subjects who voluntarily signed an informed consent form. 2. ages at ≥18 and ≤ 65 years 3. clinical diagnosis of non-segmental vitiligo. 4. all women and men who are likely to give birth must be willing to use at least one efficient method of contraception from the signing of the informed consent form to 1 month after the last dose of ip. 5. subjects who agree to discontinue all vitiligo-related treatments and camouflage cosmetics with therapeutic effect between screening visit and the last follow-up visit. 6. subjects who are willing and able to comply with the scheduled visits and treatment plan, laboratory testing and other study procedures. exclusion criteria: 1. subjects who were diagnosed with segmental vitiligo, mixed vitiligo or unclassified vitiligo. 2. subjects with historical or current evidence of clinically significant disease or lab test abnormalities or with disease that require the administration of prohibited drugs in this study. 3. subjects with a malignant tumor or a history of malignant tumor (except for fully treated or resected skin non-metastatic basal cell carcinoma or squamous cell carcinoma). 4. pregnant or lactating female subjects; 5. subjects who have previously received jak inhibitors therapy, systemic or oral 6. subjects who had used any biologics within12 weeks before the baseline or 5 half-lives (whichever is longer). 7. subjects who participated in other interventional clinical studies within 4 weeks before the baseline visit, or who were still within 5 half-lives of the last dose of the intervention clinical study drug at baseline. 8. subjects who received a live or live-attenuated vaccination within 8 weeks before the baseline visit. 9. any other condition that causes the subject to be unfit for the study as per discretion of the investigator.
endoscopic resection in gastro-esophageal reflux disease

Conditions: GERD; Gastro Esophageal Reflux

Summary: currently patients with gastroesophageal reflux disease (gerd) are treated with proton pump inhibitors (ppis). this long-term ppi treatment would likely increase the risk of pulmonary and digestive infections and would not prevent evolution to adenocarcinoma of barrett's esophagus. surgical fundoplication is generally recommended when symptoms are poorly controlled with ppis and considered as standard treatment despite celioscopy risk. a variety of endoscopic techniques for the treatment of gerd has been proposed to obtain non-surgical control. these endoscopic techniques aim to bring the tissues closer to the œsogastric (jog) junction. but a low response rate has been demonstrated with these techniques. h. inoue (inventor of the anti-reflux mucosectomy 20 years ago) and his team postulated that the reflux symptoms would be reduced by creating a relative restriction of gastric cardia. the healing of the mucosectomy zone led to restriction of gastric cardia. this observation suggested that arms could represent an effective anti-reflux procedure with the advantage that no prostheses would be left in situ. few studies have evaluated this new endoscopic technique. the purpose of this study is to evaluate the feasibility and safety of gastric mucosectomy for patients with gerd resistant to medical treatment or requiring long-term maintenance medical treatment.

this is a monocentric prospective therapeutic study. patients will be recruited in hepato-gastroenterology department of saint joseph hospital (marseille). a first clinical, endoscopic and ph impedance evaluation will be made. mucosectomy will be scheduled depending on the results of the review. the patients will be followed for 2 years with esophageal and gastric ph-impedance monitoring at 6 months and 24 months. health related quality of life questionnaires will be completed before arms, 6 and 24 months after mucosectomy. the characteristics of the patients will be compared to evaluate the % of responders and non-responders

Eligibility criteria:
inclusion criteria: * patient with gerd resistant to medical treatment, or requiring daily long-term medical treatment exclusion criteria: * contraindications to the realization of a upper gi endoscopy * achalasia or other esophageal motor disorders * voluminous hiatal hernia haemorrhagic, haemostasis or coagulation disorders
individualized precision treatment based on ovarian cancer organoid model

Conditions: Ovarian Cancer

Summary: the research purpose of this study is to use organoid cultured from patients' own ovarian cancer tissues as models, screen potential clinical therapeutic drugs (such as paclitaxel, gemcitabine, etc.) in vitro, formulate individualized drug treatment plans for individual patient, and evaluate the clinical application value of organ like drug sensitivity technology.

under the guidance of ultrasound, the lesions were punctured to obtain tumor cells; the cells were amplified and cultured by organ like culture method to establish ovarian cancer like organoid. the drug sensitivity tests of different drugs were carried out on similar organs. number of drugs tested: 10 (paclitaxel, carboplatin, lobaplatin, doxorubicin, etc.); after the test is completed, sufficient chemotherapy for full course of treatment shall be carried out according to the drug sensitivity results; after chemotherapy, blood and imaging evaluation were performed; collect the information of patients from initial treatment to the end of chemotherapy; matching the corresponding number of patients with platinum resistant relapse who did not undergo organ like culture; at each end point, the evaluation and comparison were carried out and the research conclusions were drawn.

Eligibility criteria:
inclusion criteria 1. patients diagnosed as primary nonmucous epithelial ovarian cancer with stage iii or above by previous pathological diagnosis; 2. according to the relevant standards formulated by the world health organization (who) in 2014, measurable or assessable lesions are determined; 3. platinum-resistant epithelial ovarian cancer that has received more than 2 lines of chemotherapy; 4. there is no serious disease of important organs, and the patient can tolerate chemotherapy. karnofsky score more than 60, and the expected survival period is more than half a year; 5. the liver, kidney and bone marrow functions were good. exclusion criteria 1. patients with other malignant tumors; 2. patients with nervous system diseases; 3. hepatitis b virus and human papilloma virus infection; 4. immune function defect or serious infection; 5. patients who cannot communicate effectively, disagree with the research requirements, and do not understand the research purpose.

Keywords: ovarian cancer；platinum-resistant；chemosensitivity
investigation of the effect of progressive relaxation exercises on pain and bowel movements in patients undergoing laparoscopic cholecystectomy

Conditions: Pain, Postoperative

Summary: the goal of this clinical trial is to compare in health conditions. the main questions it aims to answer are: does progressive relaxation exercises reduce pain in patients undergoing laparoscopic cholecystectomy? does progressive relaxation exercises increase bowel movements in patients undergoing laparoscopic cholecystectomy?

the purpose of our experimentally randomized controlled study, which researchers conducted in order to study the effect of progressive relaxation exercises on pain and bowel movements in patients undergoing laparoscopic cholecystectomy, is to reduce pain by intermittent application of progressive relaxation exercises to patients after surgery and to study the effect of exercise on bowel movements at an early stage. after the necessary permissions have been obtained july- september dates, van yüzüncü yıl university dursun odabaş medical center, in the general surgery clinic , patients who agree to participate in the study and meet the sample selection criteria will be included in the study. patient presentation form, bowel movement monitoring form and visual analog scale (vas) pain form will be used in the collection of research data.

Eligibility criteria:
inclusion criteria: * who experienced laparoscopic cholecystectomy surgery as planned for the first time * who volunteered to participate in the research * 18 years and over * whose mental state is healthy * without vision, hearing and speech problems * patients who know turkish were included in the study. exclusion criteria: * who have previously practiced progressive relaxation exercises * someone with communication problems * health problems that prevent the practice of progressive relaxation exercises (epilepsy, bipolar disorder, schizophrenia, fever, infection, etc. ) is * patients who were not willing to participate in the study were not included in the study.
comparison of on-line and off-line measurements of exhaled nitric oxide (no)

Conditions: Asthma; Primary Ciliary Dyskinesia

Summary: asthma is a major health problem worldwide. the measurement of fractional exhaled nitric oxide (feno) has been established as a valuable non invasive and simple tool in the diagnosis of asthma and may also act as a useful surrogate inflammatory marker on which to base treatment decisions in asthma management algorithms. the measurement is useful also in other respiratory diseases. current methods of measuring feno include on line measurements by heavy duty expensive analyzers which are not widely and easily available. off line measurements of breath samples which can be analysed later may be a simple solution. we hypothesize tha toff line measurements of no will be as reliable and valid as those measured on-line


Eligibility criteria:
inclusion criteria: * volunteer to participate * filed a short health questionnaire exclusion criteria: * none

Keywords: exhaled no off line on line comparison bland altman method
interventions for hiv+ mothers with problem drinking

Conditions: Substance Use Disorders

Summary: the purpose of this study is to evaluate the efficacy of a 14-session behavioral intervention for hiv-infected and uninfected mothers with problem drinking. the intervention targets alcohol and drug problems, sexual risk behavior, and parenting. we hypothesize that mothers in the 14-session intervention condition will show improvements in alcohol and drug use, sexual risk behavior, and parenting in comparison to the control condition, which receives a one session brief video intervention.

the purpose of this study is to evaluate the efficacy of a 14-session behavioral intervention for hiv-infected and uninfected mothers with problem drinking. we targeted 118 mothers of adolescent children (aged 11-18). the intervention is based on social action theory (ewart, 1991) and targets alcohol and drug problems, sexual risk behavior, and parenting. mothers are followed and interviewed at four intervals over 18 months. because we anticipate that the intervention will have effects on adolescent behavior, these youth are also enrolled and interviewed at three intervals over 12 months. adolescents do not attend intervention sessions. we hypothesize that mothers in the 14-session intervention condition will show improvements in alcohol and drug use, sexual risk behavior, and parenting in comparison to the control condition, which receives a one session brief video intervention.

Eligibility criteria:
inclusion criteria for adult participants (mothers): * age over 18 * meets criteria for problem drinking on the audit (score of 6 or greater) * has one biological/adopted child aged 11-18 who was in the home at least half the time in the past month exclusion criteria: * injection drug use in the past three months

Keywords: substance use disorders parent child relationship
timing of surgery and the evolution of postoperative outcomes in breast cancer patients undergoing surgical intervention following recovery from sars-cov-2 infection

Conditions: Breast Cancer; COVID-19; Postoperative Complications

Summary: perioperative sars-cov-2 infection significantly increases the risk of postoperative complications and mortality, while also exerting long-lasting impacts on multiple organs and systems. due to the curtailment or cessation of non-emergency surgeries during the initial phase of the pandemic, there is a lack of evidence regarding the optimal timing and medium- to long-term postoperative outcomes of surgical intervention in breast cancer patients with prior sars-cov-2 infection, particularly after vaccination. we aim to investigate whether prior sars-cov-2 infection increases the risk of postoperative adverse outcomes in breast cancer patients and determine the optimal timing for surgical intervention during the pandemic, as well as to longitudinally assess the evolution of postoperative adverse outcomes within one year after covid-19 and identify associated risk factors.

this study employs a prospective cohort design with longitudinal and matched characteristics, focusing on breast cancer patients who underwent surgery after recovering from sars-cov-2 infection. patients were stratified by the time of surgery relative to covid-19 diagnosis. the inverse probability of treatment weighting (iptw) method was used to match a control group (covid-19 negative) based on patient, tumor, and surgical factors in order to compare composite indicators (including death, pneumonia, thrombosis, cardiac complications, and unplanned hospitalization) for evaluating the optimal timing of surgery. we investigated the longitudinal evolution of postoperative adverse outcomes and identified the relevant risk factors through logistic regression analysis.

Eligibility criteria:
inclusion criteria: * breast cancer patients who underwent surgery after recovering from sars-cov-2 infection * breast cancer patients who had never been infected with sars-cov-2 before surgery exclusion criteria: * distant metastasis * pregnancy-associated breast cancer * incomplete follow-up information
abo-glyc in type 2 diabetes

Conditions: Type2 Diabetes

Summary: evaluation of the improvement of the overall glycemic control after 6 months of treatment with abo-glyc, as a result of reduction of hba1c and/or post-prandial glycemic peak.


Eligibility criteria:
inclusion criteria: 1. male and female patients with diagnosis of type 2 diabetes, aged 18-75 2. hba1c at screening between 6.5% and 7.5% 3. last 2 hba1c values in the last 12 months between 6.5% and 7.5% 4. intolerance to metformin without unquestionable indication to other oral hypoglycemic agents 5. bmi 25-38 kg/m2 6. willing and able to understand and sign the informed consent and complete the patient diary provided 7. women participant of childbearing age should be negative to pregnancy test (performed on blood), and will have to use an appropriate contraceptive method throughout the study. exclusion criteria: 1. micro and macrovascular complication of diabetes in advanced stage (i.e., proliferative diabetic retinopathy; chronic renal failure iii-iv stage kdoqi) 2. chronic gastro-intestinal disease 3. heavy smoker subjects 4. alcohol abuse 5. chronic liver and kidney disease (ast or alt values \> 2.5 unl or plasma creatinine \> 1.5 mg/dl) 6. previous major gastrointestinal surgery 7. history of eating disorders 8. pregnancy or lactation 9. use of food supplements containing in particular but not limited to fibers and polysaccharides, in the last six months with frequency and dosage such as to interfere with the study. 10. autoimmune diseases 11. known hypersensitivity to any of the components of the product. 12. any condition which prevent subject participation in the opinion of the principal investigator.
effects of serious games for shoulder rehabilitation

Conditions: Serious Game; Rotator Cuff Tears; Rehabilitation

Summary: the aim of this study is to examine the effect of serious-game exercise (sge) platform on pain, range of motion (rom), joint position sense, shoulder functions, and approximation force in patients with rotator cuff rupture. in addition, another objective is to evaluate the usage of balance board as a measurement tool for measuring the approximation force in the rotator cuff rupture.

purpose: to examine the effect of serious-game exercise (sge) platform on pain, range of motion (rom), joint position sense, shoulder functions, and approximation force in patients with rotator cuff rupture. in addition, another objective is to evaluate the usage of balance board as a measurement tool for measuring the approximation force in the rotator cuff rupture. method: twenty patients with rotator cuff rupture will be included in the study. they will be divided into two groups as a serious game group (sgg) and a conventional exercise group (ceg) with a randomization method. the serious game exercise program developed for shoulder rehabilitation will be applied to the sg group and conventional exercise training will be applied to the ceg. pain severity, flexion, abduction and external rotation rom, functionality, joint position sense, and approximation force of all individuals will be evaluated pre and post-treatment. sgg and ceg underwent serious games and conventional therapy twice a week for 6 weeks, respectively.

Eligibility criteria:
inclusion criteria: * being between the ages of 40-60, * having pain for more than 4 weeks, * not having had any shoulder surgery exclusion criteria: * individuals with cervical-origin neurological findings, uncooperative, different orthopedic problems in the same shoulder, * neurological, vascular and cardiac problems that limit function

Keywords: serious game rotator cuff rupture shoulder rehabilitation
a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics of hrs4800 in healthy subjects

Conditions: Pain

Summary: the study is being conducted to assess the safety and tolerability of hrs4800 after multiple oral administration with different dose regimens in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. males and females aged between 18 years and 55 years at screening, inclusive. 3. meet the weight standard 4. agree to take effective contraceptive methods 5. no clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests exclusion criteria: 1. severe infections, injuries or surgeries or plan to undergo any surgeries. 2. alt, ast, alp or total bilirubin level abnormal 3. estimated glomerular filtration rate (egfr, using ckd-epi creatinine equation) is abnormal 4. subject's supine systolic bp is \>140 mmhg or \ 90 mmhg or \<40 mmhg at screening/baseline visits or before dosing. 5. subjects with cardiac and cerebrovascular disease 6. positive nicotine test 7. history of regular alcohol consumption in the past 1 month exceeding an average weekly intake of 21 standard drinks 8. positive drug screening tests 9. positive infectious diseases screening tests 10. plan to use of any other medicine during the trial 11. whole blood donation or loss of more than 200 ml of blood within 1 month 12. blood transfusion in the past 2 months 13. history of allergy to the study drug or any component of it. 14. can't accept assigned meals during the trial 15. treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of dosing. 16. poor tolerance or difficult for vein blood collection 17. other conditions or laboratory abnormality that may increase the risk associated with study participation
inflammatory biomarkers in seizure

Conditions: Biomarkers in Seizures

Summary: 1. evaluation of the role of trail and mcp-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. possible role to predict the prognosis of patients with epileptic seizure

epilepsy is one of the most prevalent neurological disorders characterized by frequent somatic and psychiatric co-morbidities(1). accurate diagnosis of epilepsy is challenging because clinicians rarely observe the actual clinical seizure outside of the hospital. furthermore, psychogenic nonepileptic seizures (pnes) can mimic epileptic seizures (es), leading to erroneous diagnosis and inappropriate treatments. a critical gap in the diagnostic assessment of seizures is a blood test that can distinguish es from pnes (2). both diagnoses were confirmed by the gold standard diagnostic method video/electroencephalogram (eeg) monitoring (3). taking all in to account, the notion that neuro-inflammation is the key pathology behind focal epileptic seizure initiation and maintenance and the dynamic and adaptative process of neuro -inflammation is associated with blood-brain-barrier disruption and glial activation is no longer a surprise (4). tumor necrosis factor related apoptosis inducing ligand (trail) regulates immune responses via apoptosis, with lower levels associated with severe infection, including sepsis (5). monocyte chemoattractant protein-2 (mcp-2) has been well recognized to participate in immune regulation via binding to chemokine receptors and activation chemotaxis in lymphocytes t, natural killer (nk) cells, and monocytes therefore contributing to the pathogenesis of monocyte-dependent tissue injury (6). hence, mcp-2 overexpression could result in an increased immune response. further, since increased levels of mcp-2 have been observed in patients with alzheimer's disease, this may further support the existence of the biodirections relationship between neurodegeneration and seizures/epilepsy (7).

Eligibility criteria:
inclusion criteria: patients diagnosed as epileptic seizure are aged \>12 years patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years normal healthy control for comparison. heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (aed) prior to blood draw exclusion criteria: * neurological criteria: other cns disorders including parkinson's disease, amyotrophic lateral sclerosis ,cerebrovascular stroke, psychiatric disorders {major depression disorder , generalized anxiety, mania and other psychiatric diseases). others: tumors and cardiovascular